tbuckley/cabot-search huggingface dataset:
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Authors: Julie R. Lundgren, Charlotte Janus, Simon B.K. Jensen, Christian R. Juhl, Lisa M. Olsen, Rasmus M. Christensen, Maria S. Svane, Thomas Bandholm, Kirstine N. Bojsen-Møller, Martin B. Blond, Jens-Erik B. Jensen, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad, Signe S. Torekov
Journal: New England Journal of Medicine (2021)

Weight regain after weight loss is a major problem in the treatment of persons with obesity.In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed.After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group.A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).
ETHNIC DIFFERENCES IN RISK FACTORS AND EXTENT OF DISEASE AMONG PATIENTS WITH FIRST PRESENTATION OF CORONARY ARTERY DISEASE
Authors: Jasjit Rooprai, Feng Qiu, Maneesh Sud, Husam Abdel-Qadir, Carina Iskander, Douglas Lee, Mina Madan, Harindra Wijeysundera, Dennis Ko
Journal: Journal of the American College of Cardiology (2021)
ASSOCIATION OF BASELINE CORONARY PLAQUE BURDEN AND FRACTIONAL FLOW RESERVE DERIVED FROM CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) IN THE EVAPORATE TRIAL
Authors: Suvasini Lakshmanan, April Kinninger, Ilana Golub, Mark Rabbat, Campbell Rogers, Jonathon Leipsic, Deepak Bhatt, Matthew Budoff
Journal: Journal of the American College of Cardiology (2021)
RESCUE TRANSCATHETER AORTIC VALVE REPLACEMENT FOR CARDIOGENIC SHOCK DUE TO CRITICAL BICUSPID AORTIC VALVE STENOSIS
Authors: Ikenna Erinne, Arjun Theertham, Kulin Shah, Justin Johannesen, Joanna Rock, Chunguang Chen, Mark Russo, Abdul Hakeem, Deepa Iyer
Journal: Journal of the American College of Cardiology (2021)
Author Correction: Prolonged activation of innate immune pathways by a polyvalent STING agonist
Authors: Suxin Li, Min Luo, Zhaohui Wang, Qiang Feng, Jonathan Wilhelm, Xu Wang, Wei Li, Jian Wang, Agnieszka Cholka, Yang-xin Fu, Baran D. Sumer, Hongtao Yu, Jinming Gao
Journal: Nature Biomedical Engineering (2021)
Optimizing Comprehensive Performance of Aggregation‐Induced Emission Nanoparticles through Molecular Packing Modulation for Multimodal Image‐Guided Synergistic Phototherapy
Authors: Xian Wang, Luqi Liu, Li‐Juan Wang, Lianqin Guo, Yanbin Li, Bing Bai, Fan Fu, Hongguang Lu, Xiaowei Zhao
Journal: Advanced Healthcare Materials (2021)

Abstract Fluorescent nanoparticles (NPs) with aggregation‐induced emission (AIE) characteristics hold remarkable potential for image‐guided phototherapy. The molecular packing is the key point for optimizing the performance of AIE luminogens (AIEgens) in the aggregated or solid state. However, so far, the packing mode of AIEgens in NPs is still vague, causing some challenges for understanding the relationship between the photophysical property and packing mode, as well as further optimizing the performance of NPs for biomedical applications. In this contribution, by simply controlling the length of alkoxy chains in the donor–acceptor conjugated OPTPA, a packing balance between the twisted molecular structure and effective π ‐conjugation is actualized. Subsequently, the possibility of amorphous‐crystalline transition of AIEgens in the polymer‐encapsulated NPs is presented for the first time, and the comprehensive performance of NPs is further optimized. Both in vitro and in vivo experiments indicate that crystalline AIEgen‐based NPs are remarkably effective in trimodal imaging‐guided synergistic phototherapy.
RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH COVID-19 INFECTION: A META-ANALYSIS
Authors: Jan Mazur, Tam N.M. Ngo, Hoang N.H. Duong, Duy D. Nguyen, Sang T. Tran, Tam V. Nguyen, Cassady Palmer, Kim Tuyen Le, Liem T. Nguyen, Eugene Chung, Vien Truong
Journal: Journal of the American College of Cardiology (2021)
HYPERGLYCEMIA INCREASED IPILIMUMAB-INDUCED CARDIOTOXICITY, ENHANCED IMMUNE-RESISTANCE IN ERα+, PR+, HER2- BREAST CANCER CELLS MODULATING CYTOKINES AND NLRP3/MYD88 EXPRESSION
Authors: Nicola Maurea, Martina Iovine, Fabrizio Maurea, Gerardo Botti, Vincenzo Quagliariello
Journal: Journal of the American College of Cardiology (2021)
Wireless and Flexible Skin Moisture and Temperature Sensor Sheets toward the Study of Thermoregulator Center
Authors: Yuyao Lu, Yusuke Fujita, Satoko Honda, Shin‐Hsin Yang, Yan Xuan, Kaichen Xu, Takayuki Arie, Seiji Akita, Kuniharu Takei
Journal: Advanced Healthcare Materials (2021)

A disorder in the thermoregulator center in a human body leads to some potential diseases such as fever and hyperthyroidism. To predict these diseases early, monitoring the health condition of the human body due to the influence of thermoregulation disorders is important. Although extensive works are performed on sweat-rate detection by constructing microfluidic channels, skin-moisture evaporation before sweating remains unknown. This work proposes a wireless and flexible sensor sheet to investigate the thermoregulatory responses of different people under cold stimulation and exercise by measuring the temperature and moisture variations on the finger skin. An integrated flexible sensor system consists of a ZnIn2 S4 nanosheet-based humidity sensor and carbon nanotube/SnO2 temperature sensor. The results exhibit distinct thermoregulation abilities of five volunteers. Interestingly, the sudden increase in finger moisture that results from the excitation by the sympathetic nerve is observed during the cold-stimulus test. Although further studies are required to predict the potential diseases resulted from thermoregulation disorders in human body, this study provides a possibility of continuous and real-time monitoring of thermoregulatory activities via skin moisture and temperature detection using a flexible sensor sheet.
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Authors: Jacky Yeung, Vesal Yaghoobi, Danielle Miyagishima, Matthew D Vesely, Tianxiang Zhang, Ti Badri, Ala Nassar, Xue Han, Miguel F Sanmamed, Mark Youngblood, Matthieu Peyre, Michel Kalamarides, David L Rimm, Murat Gunel, Lieping Chen
Journal: Neuro-Oncology (2021)

Abstract Background Malignant meningiomas are fatal and lack effective therapy. As M2 macrophages are the most prevalent immune cell type in human meningiomas, we hypothesized that normalizing this immunosuppressive population would be an effective treatment strategy. Methods We used CIBERSORTx to examine the proportions of 22 immune subsets in human meningiomas. We targeted the colony-stimulating factor 1 (CSF1) or CSF1 receptor (CSF1R) axis, an important regulator of macrophage phenotype, using monoclonal antibodies (mAbs) in a novel immunocompetent murine model (MGS1) for malignant meningioma. RNA sequencing (RNA-seq) was performed to identify changes in gene expression in the tumor microenvironment (TME). Mass cytometry was used to delineate changes in immune subsets after treatment. We measured patients’ plasma CSF1 levels using ELISA and CSF1R expression using multiplex quantitative immunofluorescence in a human meningioma tissue microarray. Results Human meningiomas are heavily enriched for immunosuppressive myeloid cells. MGS1 recapitulates the TME of human meningiomas, including an abundance of myeloid cells, a paucity of infiltrating T cells, and low programmed death ligand 1 (PD-L1) expression. Treatment of murine meningiomas with anti-CSF1/CSF1R, but not programmed cell death receptor 1 (PD-1), mAbs abrogate tumor growth. RNA-seq and mass cytometry analyses reveal a myeloid cell reprogramming with limited effect on T cells in the TME. CSF1 plasma levels are significantly elevated in human patients, and CSF1R is highly expressed on CD163+ macrophages within the human TME. Conclusion Our findings suggest that anti-CSF1/CSF1R antibody treatment may be an effective normalization cancer immunotherapy for malignant meningiomas.
METHODOLOGY FOR MEMBRANOUS SEPTUM LENGTH EVALUATION TO PREDICT PERMANENT PACEMAKER FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: AN EVIDENCE-BASED COMPARATIVE STUDY
Authors: Makoto Nakashima, Yuxin He, Zhengang Zhao, Run Du, Michael Querijero, Cezar Staniloae, Homam Ibrahim, Joseph Tovar, Illya Pushkar, Mathew Williams, Hasan Jilaihawi
Journal: Journal of the American College of Cardiology (2021)
Vaccination Priorities Delay Shots for Higher-Risk People of Color
Authors: Rita Rubin
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ACCURACY OF CARDIOVASCULAR TRIAL OUTCOME ASCERTAINMENT AND TREATMENT EFFECT ESTIMATES FROM ROUTINE HEALTH DATA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Craig Rodrigues, Ayodele Odutayo, Sagar Patel, Arnav Argarwal, Bruno Roza da Costa, Ethan Lin, Robert Yeh, Peter Juni, Shaun Goodman, Michael Farkouh, Jacob Udell
Journal: Journal of the American College of Cardiology (2021)
James Alexander May Findlay
Authors: Elspeth Jajdelska
Journal: BMJ (2021)

James Alexander May Findlay, known to friends and family as Alastair, was born in the family home in Fraserburgh, a fishing town in the north east of Scotland. He was the youngest of three siblings; Jean and Betty were seven and 13 years older, respectively. Their father worked for many years as a plumber before his appointment as the town’s water inspector. The Findlays lived in a council flat. Alastair’s mother left school at 14 to go into service for the family of a professor in Boston, and she placed a high value on education. Alastair worked hard at school to earn a university place, but he found time for sport, playing for the town’s cricket team. His time as a medical student at Aberdeen University was characterised by intense study …
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer
Authors: Xia Liu, Valery Adorno-Cruz, Ya-Fang Chang, Yuzhi Jia, Madoka Kawaguchi, Nurmaa K Dashzeveg, Rokana Taftaf, Erika K Ramos, Emma J Schuster, Lamiaa El-Shennawy, Dhwani Patel, Youbin Zhang, Massimo Cristofanilli, Huiping Liu
Journal: Theranostics (2021)

Triple-negative breast cancer (TNBC) is one of the most aggressive and metastatic breast cancer subtypes lacking targeted therapy. Our recent work demonstrated that circulating tumor cell (CTC) clusters and polyclonal metastasis of TNBC are driven by aggregation of CD44+ cancer stem cells (CSC) and associated with an unfavorable prognosis, such as low overall survival. However, there is no existing therapeutic that can specifically block CTC or CSC cluster formation. Methods: Using patient-derived xenograft (PDX) models, we established an ex vivo tumor cell clustering assay for a pilot screening of blockade antibodies. After identifying EGFR as a target candidate, we modulated the gene expression and inhibited its kinase activity to determine its functional importance in tumor cell clustering and therapeutic inhibition of lung metastasis. We also examined the molecular regulation network of EGFR and a potential connection to CSC marker CD44 and microRNAs, which regulate CTC clustering. Results: We report here that EGFR inhibition successfully blocks circulating CSC (cCSC) clustering and lung metastasis of TNBC. EGFR enhances CD44-mediated tumor cell aggregation and CD44 stabilizes EGFR. Importantly, blocking EGFR by a novel anti-EGFR monoclonal antibody (clone LA1) effectively blocked cell aggregation in vitro and reduced lung metastasis in vivo. Furthermore, our data demonstrated that the tumor suppressor microRNA-30c serves as another negative regulator of cCSC clustering and lung metastasis by targeting CD44 as well as its downstream effector EGFR. Conclusion: Our studies identify a novel anti-EGFR therapeutic strategy to inhibit cCSC aggregation and therefore abolish cCSC cluster-mediated metastasis of TNBC.
SARS-COV-2 PLATELET FUNCTION &amp; THROMBOTIC COMPLICATIONS: EFFECTS OF ASPIRIN THERAPY IN COVID-19
Authors: Rohan Bhandari, Aditya Sahai, Ayman Elbadawi, Islam Elgendy, Milka Koupenova, Jane Freedman, Matthew Godwin, Anu Aggarwal, Livia Timpanaro-Perotta, Mina Chung, Thomas McIntyre, Ankur Kalra, John Bartholomew, Keith McCrae, Lars Svensson, Samir Kapadia, Scott Cameron
Journal: Journal of the American College of Cardiology (2021)
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
Authors: Yasuto Yoneshima, Satoshi Morita, Masahiko Ando, Atsushi Nakamura, Shunichiro Iwasawa, Hiroshige Yoshioka, Yasuhiro Goto, Masafumi Takeshita, Toshiyuki Harada, Katsuya Hirano, Tetsuya Oguri, Masashi Kondo, Satoru Miura, Yukio Hosomi, Terufumi Kato, Toshio Kubo, Junji Kishimoto, Nobuyuki Yamamoto, Yoichi Nakanishi, Isamu Okamoto
Journal: Journal of Thoracic Oncology (2021)

IntroductionWe aimed to evaluate the efficacy and safety of nanoparticle albumin-bound (nab-) paclitaxel for previously treated patients with advanced NSCLC.MethodsIn this randomized, open-label, noninferiority phase 3 trial, we enrolled patients with advanced NSCLC previously treated with cytotoxic chemotherapy. Patients were randomly allocated (1:1) to receive docetaxel (60 mg/m2) on day 1 or nab-paclitaxel (100 mg/m2) on days 1, 8, and 15 of a 21-day cycle. The primary end point was overall survival (OS) analyzed on an intention-to-treat basis.ResultsBetween May 22, 2015, and March 12, 2018, a total of 503 patients were randomly allocated to the treatment. Median OS was 16.2 months (95% confidence interval [CI]: 14.4–19.0) for the 252 patients allocated to nab-paclitaxel and 13.6 months (95% CI: 10.9–16.5) for the 251 patients allocated to docetaxel (hazard ratio = 0.85, 95.2% CI: 0.68–1.07). Median progression-free survival was 4.2 months (95% CI: 3.9–5.0) for the nab-paclitaxel group versus 3.4 months (95% CI: 2.9–4.1) for the docetaxel group (hazard ratio = 0.76, 95% CI: 0.63–0.92, p = 0.0042). The objective response rate was 29.9% (95% CI: 24.0–36.2) for the nab-paclitaxel group and 15.4% (95% CI: 10.9–20.7) for the docetaxel group (p = 0.0002). Adverse events of grade greater than or equal to 3 included febrile neutropenia (5 of 245 patients [2%] in the nab-paclitaxel group versus 55 of 249 patients [22%] in the docetaxel group) and peripheral sensory neuropathy (24 [10%] versus 2 [1%], respectively).ConclusionsNab-paclitaxel was noninferior to docetaxel in terms of OS. It should, thus, be considered a standard treatment option for previously treated patients with advanced NSCLC.
IMPACT OF COVID-19 ON CARDIOVASCULAR FELLOWSHIP ECHOCARDIOGRAPHY TRAINING IN A TERTIARY ACADEMIC PROGRAM
Authors: Kushani Gajjar, Adee Elhamdani, Kartikeya Kashyap, Daniel Pyle, Mark Doyle, Rachel Hughes-Doichev, Robert W.W. Biederman
Journal: Journal of the American College of Cardiology (2021)
MULTI-PARAMETRIC PHENOMAPPING USING MACHINE LEARNING IDENTIFIES A NOVEL SUBTYPE OF DILATED CARDIOMYOPATHY AND HIGHLIGHTS IL4R AS A NOVEL PROGNOSTIC BIOMARKER
Authors: Upasana Tayal, Job verdonschot, Mark hazebroek, Chee Jian Pua, Amrit Lota, Brian Halliday, Jackie Donovan, Michael Paul Frenneaux, John Cleland, Stuart Cook, Stephane Heymans, Rahul Deo, Sanjay Prasad
Journal: Journal of the American College of Cardiology (2021)
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
Authors: Michael Grever, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema Bhat, James S. Blachly, Timothy Call, Matthew Cross, Claire Dearden, Judit Demeter, Sasha Dietrich, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Gunnar Juliusson, Eric Kraut, Robert J. Kreitman, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae Park, Aaron Polliack, Farhad Ravandi, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Enrico Tiacci, Xavier Troussard, Clive Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann
Journal: Leukemia (2021)

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.
PROGNOSTIC VALUE OF COMPUTED TOMOGRAPHY DERIVED FRACTIONAL FLOW RESERVE COMPARISON WITH MYOCARDIAL PERFUSION IMAGING
Authors: Ahmed Ibrahim Ahmed, Yushui Han, Faisal Nabi, Su Min Chang, Talal Alnabelsi, Myra Cocker, Chris Schwemmer, William Zoghbi, John Mahmarian, Mouaz Al-Mallah
Journal: Journal of the American College of Cardiology (2021)
EFFECT OF DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE ON CARDIAC FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED AL AMYLOIDOSIS WITH CARDIAC INVOLVEMENT: RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
Authors: Martha Grogan, Mathew S. Maurer, Ronald Witteles, Divaya Bhutani, Raymond L. Comenzo, Angela Dispenzieri, Arnaud Jaccard, Efstathios Kastritis, Michaela Liedtke, Giampaolo Merlini, Monique C. Minnema, Vaishali Sanchorawala, Katharine S. Gries, Xiang Qin, Huiling Pei, NamPhuong Tran, Brendan M. Weiss, Ashutosh D. Wechalekar
Journal: Journal of the American College of Cardiology (2021)
Prevalence and variability of current depressive disorder in 27 European countries: a population-based study
Authors: Jorge Arias-de la Torre, Gemma Vilagut, Amy Ronaldson, Antoni Serrano-Blanco, Vicente Martín, Michele Peters, Jose M Valderas, Alex Dregan, Jordi Alonso
Journal: The Lancet Public Health (2021)

BackgroundWe aimed to estimate the prevalence of current depressive disorder in 27 European countries, and to explore differences in prevalence between European countries and by gender.MethodsIn this population-based study, we analysed data from respondents living in 27 European countries who were included in the second wave of the European Health Interview Survey, collected between 2013 and 2015. We assessed the prevalence of current depressive disorder using the eight-item Patient Health Questionnaire (PHQ-8), with depressive disorder defined as a PHQ-8 score of 10 or higher. Prevalence estimates and 95% CIs were calculated for all 27 countries overall and for each country individually. We assessed variation in prevalence (country vs the rest of Europe) using crude and adjusted prevalence ratios obtained from negative binomial regression models. We did all analyses for the total sample and stratified by gender.FindingsOur analysis sample comprised 258 888 individuals, of whom 117 310 (weighted proportion 47·8%) were men and 141 578 (52·2%) were women. The overall prevalence of current depressive disorder was 6·38% (95% CI 6·24–6·52) with important variation across countries, ranging from 2·58% (2·14–3·02) in the Czech Republic to 10·33% (9·33–11·32) in Iceland. Prevalence was higher in women (7·74% [7·53–7·95]) than in men (4·89% [4·71–5·08]), with clear gender differences for all countries except Finland and Croatia. Compared with the other European countries in our sample, those with the highest adjusted prevalence ratios were Germany (1·80 [1·71–1·89]) and Luxembourg (1·50 [1·35–1·66]), and those with the lowest adjusted prevalence ratios were Slovakia (0·28 [0·24–0·33]) and the Czech Republic (0·32 [0·27–0·38]).InterpretationDepressive disorders, although common across Europe, vary substantially in prevalence between countries. These results could be a baseline for monitoring the prevalence of current depressive disorder both at a country level in Europe and for planning health-care resources and services.FundingUK Medical Research Council and CIBER Epidemiology and Public Health (CIBERESP).
Targeting androgen signaling in ILC2s protects from IL-33–driven lung inflammation, independently of KLRG1
Authors: Eve Blanquart, Audrey Mandonnet, Marion Mars, Claire Cenac, Nina Anesi, Pascale Mercier, Christophe Audouard, Stephane Roga, Gilberto Serrano de Almeida, Charlotte L. Bevan, Jean-Philippe Girard, Lucette Pelletier, Sophie Laffont, Jean-Charles Guéry
Journal: Journal of Allergy and Clinical Immunology (2021)
Metallic Thin Films: The Synergy of Topographical Micropatterning and Ta|TaCu Bilayered Thin Film on Titanium Implants Enables Dual‐Functions of Enhanced Osteogenesis and Anti‐Infection (Adv. Healthcare Mater. 9/2021)
Authors: Mingyu Zhu, Ju Fang, Yulei Li, Chuanxin Zhong, Shihui Feng, Xiang Ge, Haixia Ye, Xiaofei Wang, Weiwei Zhu, Xiong Lu, Fuzeng Ren
Journal: Advanced Healthcare Materials (2021)